Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Veltin
CTGel/ BPO Wash · 1 trial · 1 indication
Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application. Grading will use the following scale: 0 - None 1. \- Trace 2. \- Mild 3. \- Moderate 4. \- Marked 5. \- Severe
Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application. Grading will use the following scale: 0 - None 1. \- Trace 2. \- Mild 3. \- Moderate 4. \- Marked 5. \- Severe
Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application. Grading will use the following scale: 0 - None 1. \- Trace 2. \- Mild 3. \- Moderate 4. \- Marked 5. \- Severe
| Arm | Type | Description |
|---|---|---|
| CTGel plus BPO wash | EXPERIMENTAL | Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening |
| CTGel | ACTIVE_COMPARATOR | Soap Free Cleanser in the morning and CTGel in the evening |
| Name | Type | Description |
|---|---|---|
| CTGel/ BPO Wash | DRUG | Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days. |
| Soap Free Cleanser and CTGel | DRUG | Soap Free Cleanser will be used once daily in the morning for 28 days Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days. |
Inclusion Criteria: * Subjects with mild to moderate facial acne vulgaris, with no history of known or suspected hypersensitivity or previous allergic reaction to any of the ingredients of the study products (eg, topical antibiotics, retinoids or benzoyl peroxide), capable of understanding and will...
CTGel/ BPO Wash is an investigational topical combination regimen being developed by GSK plc for acne vulgaris. It pairs a topical antibiotic and retinoid gel with a benzoyl peroxide wash. It is a small molecule dermatology asset and has been studied in a Phase 3 clinical trial.
CTGel/ BPO Wash is being developed for the treatment of acne vulgaris. The regimen combines a topical antibiotic and retinoid gel with a benzoyl peroxide wash. It is intended for patients with acne, including adolescents, as the trial enrolled participants aged 12 years and older.
GSK plc, which trades under the ticker GSK, is the developer of CTGel/ BPO Wash. The company is advancing this topical acne regimen through clinical development in dermatology.
CTGel/ BPO Wash has completed a Phase 3 clinical trial. It is an investigational product and is not approved for marketing. The completed Phase 3 study evaluated the tolerability of the combined regimen in acne vulgaris.
CTGel/ BPO Wash has been studied in one completed Phase 3 trial, NCT00891982, titled a clinical study to evaluate the tolerability of a topical antibiotic and retinoid used in a combined regimen with a BPO wash. The trial enrolled 60 participants with acne vulgaris in the United States.
The Phase 3 trial NCT00891982 was an active-controlled study that enrolled 60 participants with acne vulgaris. It was randomized but not double-blind, and it included participants aged 12 years and older of all sexes. The study was conducted in the United States and has been completed.